Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling

European Journal of Clinical Investigation

Volumn 43, Issue 6, 2013, Pages 570-578

  Mahmut, Ablajan ^a   Boulanger, Marie Chloé ^a   Fournier, Dominique ^a   Couture, Christian ^a   Trahan, Sylvain ^a   Pagé, Sylvain ^a   Arsenault, Benoît ^a   Després, Jean Pierre ^a   Pibarot, Philippe ^a   Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Calcific aortic stenosis; Calcific aortic valve disease; High density lipoprotein; Lipoprotein lipase; Oxidized LDL; Remodelling

Indexed keywords

CHOLESTEROL; DECORIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGED; AORTA VALVE STENOSIS; ARTICLE; CALCIFICATION; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; FEMALE; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; VASCULAR CALCIFICATION;

EID: 84877705895     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12081     Document Type: Article

References (39)

1. Cote N, Couture C, Pibarot P, Despres JP, Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011;41:1172-9.
2. Rajamannan NM. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009;29:162-8.
3. Cote C, Pibarot P, Despres JP, Mohty D, Cartier A, Arsenault BJ et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175-80.
4. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124:1783-91.
5. Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995;76:928-32.
6. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987;59:998-9.
7. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? A clinical morphologic study Clin Cardiol 1991;14:995-9.
8. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
9. Zezulka A, Mackinnon J, Beevers DG. Hypertension in aortic valve disease and its response to valve replacement. Postgrad Med J 1992;68:180-5.
10. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22.
11. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
12. Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. J Am Coll Cardiol 2012;60:216-23.
13. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
14. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
15. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-14.
16. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, Cartier A et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008;28:187-93.
17. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577-84.
18. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006;47:2229-36.
19. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006;113:2113-9.
20. Mathieu P, Pibarot P, Despres JP. Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manag 2006;2:285-302.
21. Audet A, Cote N, Couture C, Bosse Y, Despres JP, Pibarot P et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology 2012;61:610-19.
22. Parra S, Vives G, Ferre R, Gonzalez M, Guardiola M, Ribalta J et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis 2012;225:224-30.
23. Cote N, Pibarot P, Pepin A, Fournier D, Audet A, Arsenault B et al. Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2010;145:444-9.
24. Cote N, Mahmut A, Bosse Y, Couture C, Page S, Trahan S et al. Inflammation is associated with the remodeling of calcific aortic valve disease. Inflammation 2012 doi:10.1007/s10753-012-9579-6 (in press).
25. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg IJ, Steinberg D, Witztum JL. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:10143-7.
26. O'Brien KD, Gordon D, Deeb S, Ferguson M, Chait A. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J Clin Invest 1992;89:1544-50.
27. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005;25:2062-8.
28. Edwards IJ, Goldberg IJ, Parks JS, Xu H, Wagner WD. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. J Lipid Res 1993;34:1155-63.
29. Warren BA, Yong JL. Calcification of the aortic valve: its progression and grading. Pathology 1997;29:360-8.
30. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553-9.
31. Hogue JC, Lamarche B, Gaudet D, Tremblay AJ, Despres JP, Bergeron J et al. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis 2007;190:429-35.
32. Roberts WC, Ko JM. Weights of operatively-excised stenotic unicuspid, bicuspid, and tricuspid aortic valves and their relation to age, sex, body mass index, and presence or absence of concomitant coronary artery bypass grafting. Am J Cardiol 2003;92:1057-65.
33. Syvanne M, Ahola M, Lahdenpera S, Kahri J, Kuusi T, Virtanen KS et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36:573-82.
34. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2670-6.
35. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Despres JP. Visceral obesity and the heart. Int J Biochem Cell Biol 2008;40:821-36.
36. Pascot A, Lemieux I, Prud'homme D, Tremblay A, Nadeau A, Couillard C, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001;42:2007-14.
37. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
38. Kovanen PT, Pentikainen MO. Decorin links low-density lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc Med 1999;9:86-91.
39. Pentikainen MO, Oorni K, Kovanen PT. Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen. Roles for both dimeric and monomeric forms of LPL. J Biol Chem 2000;275:5694-701.